Prosecution Insights
Prosecution Insights
43 pending office actions • 24 art units • 40 examiners • 0 of 43 (0%) have an AI response strategy ready • 48 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 18 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 18 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (5%) |
| §101 + other | 3 (7%) |
| §103 only | 5 (12%) |
| §102 only | 1 (2%) |
| §112 only | 11 (26%) |
| Double-patenting only | 2 (5%) |
| Double-patenting + other | 7 (16%) |
| Multi-statute (no §101) | 12 (28%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 2 | 65.0% | +9.2% |
| GIBBS, TERRA C | 2 | 63.9% | +10.4% |
| FOLEY, SHANON A | 2 | 73.2% | +18.0% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.8% |
| NOTTINGHAM, KYLE GREGORY | 1 | 59.3% | +34.9% |
| CHENG, KAREN | 1 | 76.3% | +27.1% |
| BERRY, LAYLA D | 1 | 65.9% | +8.9% |
| GUTIERREZ, GISSELLE M | 1 | 80.5% | +12.8% |
| FONTAINHAS, AURORA M | 1 | 38.0% | +49.1% |
| TRAN, SUSAN T | 1 | 62.6% | +35.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686991 | METHOD OF DETERMINING A FUTURE COLOR VALUE OR CORRESPONDING PROPERTY AND ARRANGEMENT THEREFOR | GUTIERREZ, GISSELLE M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | MCCOLLUM, ANDREA K | 44d overdue |
| 17999122 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | SHIN, DANA H | 23d overdue |
| 17914373 | USE OF BIOMARKERS IN THE TREATMENT OF FIBROTIC CONDITIONS | BOESEN, CHRISTIAN C | 5d |
| 18298882 | COMBINATION TREATMENT | SHIBUYA, MARK LANCE | 15d |
| 18413822 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | TRAN, SUSAN T | 28d |
| 18221936 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | MOORE, SUSANNA | 28d |
| 18039433 | ADMINISTRATION DEVICE FOR IN PARTICULAR INTRAVITREAL ADMINISTRATION OF A FLUID | BRANDT, DAVID NELSON | 30d |
| 18482334 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN FELINES | LAU, JONATHAN S | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003056 | COMBINATION PORCINE VACCINE | FOLEY, SHANON A | 31d overdue |
| 18413822 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | TRAN, SUSAN T | 28d |
| 18295675 | IMMUNOGENIC COMPOSITION USEFUL FOR VACCINATION AGAINST ROTAVIRUS | FOLEY, SHANON A | 55d |
| 18801886 | Cardiosafe Antidiabetic Therapy | BAEK, BONG-SOOK | — |
| 18789814 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | NOTTINGHAM, KYLE GREGORY | — |
| 18700748 | TRPC6 INHIBITORY COMPOUNDS FOR TREATING SEPSIS | CHENG, KAREN | — |
| 18686991 | METHOD OF DETERMINING A FUTURE COLOR VALUE OR CORRESPONDING PROPERTY AND ARRANGEMENT THEREFOR | GUTIERREZ, GISSELLE M | — |
| 18423352 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES | FONTAINHAS, AURORA M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 4 |
| 1635 | 3 |
| 1671 | 3 |
| 1693 | 2 |
| 1699 | 2 |
| 1675 | 2 |
| 1642 | 2 |
| 3796 | 2 |
| 1623 | 1 |
| 2884 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18801886 | Cardiosafe Antidiabetic Therapy | BAEK, BONG-SOOK | — | §103 | Final Rejection | — | Pending | Aug 13, 2024 |
| 18789814 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | NOTTINGHAM, KYLE GREGORY | — | §112 | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18785078 | PROCESS FOR THE MANUFACTURE OF A HER2 INHIBITOR | OTTON, ALICIA L | — | §112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18700748 | TRPC6 INHIBITORY COMPOUNDS FOR TREATING SEPSIS | CHENG, KAREN | 1623 | §103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18597314 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BERRY, LAYLA D | 1693 | §103 | Final Rejection | 66d overdue | Pending | Mar 06, 2024 |
| 18686991 | METHOD OF DETERMINING A FUTURE COLOR VALUE OR CORRESPONDING PROPERTY AND ARRANGEMENT THEREFOR | GUTIERREZ, GISSELLE M | 2884 | §112 | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18423352 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES | FONTAINHAS, AURORA M | — | §102§112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18413822 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | TRAN, SUSAN T | 1615 | §103§112 | Non-Final OA | 28d | Pending | Jan 16, 2024 |
| 18561823 | A METHOD AND SYSTEM FOR INTEGRATED AND CONTINUOUS VIRAL FILTRATION, CONCENTRATION AND BUFFER EXCHANGE | MOAZZAMI, NAGHMEH NINA | 1652 | §102§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18561842 | TITER METHOD USING UV MEASUREMENT FOR CONTINUOUS BIOLOGICAL PRODUCTION | LEE, BYUNG RO | — | §101§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18493126 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BARSKY, JARED | 1628 | DP | Final Rejection | — | Pending | Oct 24, 2023 |
| 18554231 | ANTICANCER THERAPY | JARRELL, NOBLE E | 1699 | §103 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18474419 | Use of Biomarkers in the Treatment of Fibrotic Conditions with a PDE4B-inhibitor | MACFARLANE, STACEY NEE | 1675 | §101 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18468885 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | MCDOWELL, BRIAN E | 1624 | §112 | Final Rejection | 22d | Pending | Sep 18, 2023 |
| 18275616 | ANTI-IL1RAP ANTIBODIES | NICKOL, GARY B | 1643 | §102§112 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | MCCOLLUM, ANDREA K | 1674 | §103§112Other | Non-Final OA | 44d overdue | Pending | Jul 17, 2023 |
| 18221936 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | MOORE, SUSANNA | 1624 | §103§112 | Non-Final OA | 28d | Pending | Jul 14, 2023 |
| 18259098 | VIRAL CAPSID PROTEINS WITH SPECIFICITY TO HEART TISSUE CELLS | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | — | Pending | Jun 23, 2023 |
| 18256777 | FORMULATION FOR MULTI-PURPOSE APPLICATION | LU, CHENG | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18327255 | HUMAN ANTIBODIES TO TN ANTIGEN | MIDDLETON, DANAYA L | 1618 | §112 | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18039433 | ADMINISTRATION DEVICE FOR IN PARTICULAR INTRAVITREAL ADMINISTRATION OF A FLUID | BRANDT, DAVID NELSON | 3783 | §102§103§112 | Non-Final OA | 30d | Pending | May 30, 2023 |
| 18251562 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103§112DP | Non-Final OA | — | Pending | May 03, 2023 |
| 18251571 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF | GIBBS, TERRA C | 1635 | §112Other | Non-Final OA | — | Pending | May 03, 2023 |
| 18298882 | COMBINATION TREATMENT | SHIBUYA, MARK LANCE | 1631 | §103§112Other | Non-Final OA | 15d | Pending | Apr 11, 2023 |
| 18185493 | ANG2-BINDING MOLECULES | MOSELEY II, NELSON B | 1642 | §112Other | Non-Final OA | 5d | Pending | Mar 17, 2023 |
| 18044110 | METHOD FOR DETECTING CONTAMINATING LIPASE ACTIVITY | CURRENS, GRANT CARSON | 1651 | §103§112 | Non-Final OA | — | Pending | Mar 06, 2023 |
| 18019771 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | 4d overdue | Pending | Feb 03, 2023 |
| 18001980 | A METHOD OF PROVIDING A HOMOGENEOUS FEED STREAM WITHIN A PLUG FLOW REACTOR | HUANG, RYAN | 1777 | §102 | Final Rejection | — | Pending | Dec 15, 2022 |
| 17999122 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | SHIN, DANA H | 1635 | §101§102§103§112 | Non-Final OA | 23d overdue | Pending | Nov 17, 2022 |
| 17914373 | USE OF BIOMARKERS IN THE TREATMENT OF FIBROTIC CONDITIONS | BOESEN, CHRISTIAN C | 1684 | §101§103 | Non-Final OA | 5d | Pending | Sep 26, 2022 |
| 17785427 | BIFUNCTIONAL MOLECULES COMPRISING AN IL-7 VARIANT | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112DP | Non-Final OA | — | Pending | Jun 15, 2022 |
| 17525433 | CELL ENGINEERING USING RNAs | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | 34d | Pending | Nov 12, 2021 |
| 17608328 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF PF-ILD AND IPF | ZAHORIK, AMANDA MARY | 1636 | §112DP | Final Rejection | 119d overdue | Pending | Nov 02, 2021 |
| 18666911 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | REDWOOD, CHRISTOPHER EVAN | — | §102§103§112DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18666922 | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan | SHIAO, YIH-HORNG | — | DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18482334 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN FELINES | LAU, JONATHAN S | 1693 | §103§112Other | Non-Final OA | 34d | Pending | Oct 06, 2023 |
| 18481566 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | BRAUN, MADELINE E | 1624 | §112 | Non-Final OA | 20d | Pending | Oct 05, 2023 |
| 18252590 | NEW FELINE HERPES VIRUS VACCINE | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | — | Pending | May 11, 2023 |
| 18295675 | IMMUNOGENIC COMPOSITION USEFUL FOR VACCINATION AGAINST ROTAVIRUS | FOLEY, SHANON A | 1671 | §103§112Other | Final Rejection | 55d | Pending | Apr 04, 2023 |
| 18159241 | ANALYSIS OF AN ACOUSTIC SIGNAL | HOLMES, REX R | 3796 | §101 | Final Rejection | — | Pending | Jan 25, 2023 |
| 17131312 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS | OTTON, ALICIA L | 1699 | §112 | Non-Final OA | 27d | Pending | Dec 22, 2020 |
| 17070968 | EXAMINATION APPARATUS FOR MEDICAL EXAMINATION OF AN ANIMAL | HADDAD, MOUSSA MAHER | 3796 | §103§112 | Non-Final OA | — | Pending | Oct 15, 2020 |
| 18003056 | COMBINATION PORCINE VACCINE | FOLEY, SHANON A | 1671 | §103 | Non-Final OA | 31d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial